COMMUNIQUÉS West-GlobeNewswire

Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
05/03/2024
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas [...]
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
05/03/2024
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on [...]
Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024
05/03/2024
New data in gastro-esophageal and lung cancers show the transformative potential of the platform in providing resolution into the activation status of clinically actionable genes and pathways from a simple blood draw [...]
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
05/03/2024
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC) PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- [...]
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, a G12V-preferring multi-KRAS inhibitor, at AACR Annual Meeting
05/03/2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today announced it will give a [...]
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
05/03/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
05/03/2024
5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American [...]
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
05/03/2024
Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutations CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE [...]
Tarsus to Participate at Upcoming Investor Conferences
05/03/2024
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for [...]
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
05/03/2024
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidates Strong preclinical activity across multiple FRα- [...]
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
05/03/2024
New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented. The platform has demonstrated the ability to [...]
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
05/03/2024
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight [...]
Immunocore presented two posters at CROI 2024
05/03/2024
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 March [...]
Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting
05/03/2024
CAMBRIDGE, United Kingdom, March 05, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients, [...]
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
05/03/2024
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally [...]
iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024
05/03/2024
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”) , an online global marketplace that connects scientists requiring biospecimens for medical research with [...]
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
05/03/2024
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for [...]
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
05/03/2024
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: [...]
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
05/03/2024
- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc [...]

Pages